Workflow
Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
solo stovesolo stove(US:DTC) Newsfile·2025-10-02 07:15

Core Insights - Defence Therapeutics Inc. has appointed Dr. Mark Lambermon as Head of Quality and Operations, bringing over 20 years of experience in pharmaceutical R&D and biotech innovation [1][2] - Dr. Lambermon's expertise will be crucial for the company's regulatory readiness and operational excellence as it advances its drug delivery technologies [3] - The company has granted Dr. Lambermon 100,000 incentive stock options, exercisable at $0.80 per share for three years [4] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells [5]